The study sample included patients aged ≥ 18 year who were suspected CRBSI from January 2009 to December 2018. All available patients were included: 642 in the non-CRBSI group and 153 in the CRBSI group. Assuming a mortality rate of 25.96% with CRBSI [15] and 10.9% with ICU-acquired infections [2], we calculated that group sample sizes of 209 in non-CRBSI group and 105 in CRBSI group achieve 80% power to detect a ratio in the group proportions of 0.5 by the PASS 11 software (NCSS, LLC. Kaysville, Utah, USA. www.ncss.com.).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.